Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2020

Published	Pages	Publisher	Report code
Jan 2020	116	Global Markets Direct	ASDR-506322

Published: Jan 2020 - Pages : 116 - Publisher : Global Markets Direct - Report code : ASDR-506322

Achillion Pharmaceuticals Inc
Aevitas Therapeutics Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Amgen Inc
ChemoCentryx Inc
Greenovation Biotech GmbH
Omeros Corp
Ra Pharmaceuticals Inc
Turgut Ilaclari AS

Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

This report can be of interest as well:

Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) Drugs in Development by Stages, ...

Published: March, 2022 | Report code: ASDR-599078